Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

The US Food and Drug Administration (FDA) has put on hold all respiratory syncytial virus (RSV) vaccine trials involving infants (aged under 2 years) or RSV naive children aged 2-5 years, after a ...

Chances of Malaysians getting their hands on updated Covid-19 vaccines appear dim following what appears to be a lack of ...

MicroStrategy has expanded its board of directors, appointing former Binance.US CEO Brian Brooks along with Jane Dietze and ...

Moderna Inc. closed $131.08 below its 52-week high ($170.47), which the company achieved on May 24th.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

To understand how Summit Therapeutics ( SMMT 8.36%) could turn an investment of $1,000 into $5,000 by 2030, we need to first ...

This study reveals how SARS-CoV-2 infection significantly alters human milk composition, while COVID-19 vaccination causes ...

Fintel reports that on December 18, 2024, Argus Research downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

However, in July 2024, manufacturer Moderna halted its study because of concerns about severe side effects in a subset of ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...